Hudson Vegas Investment Spv, L Sells 50,000 Shares of P3 Health Partners (NASDAQ:PIII) Stock

P3 Health Partners Inc. (NASDAQ:PIII) major shareholder Hudson Vegas Investment Spv, L sold 50,000 shares of P3 Health Partners stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $16.48, for a total transaction of $824,000.00. Following the sale, the insider owned 48,959 shares in the company, valued at approximately $806,844.32. This trade represents a 50.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

P3 Health Partners Trading Down 5.5%

NASDAQ:PIII traded down $0.68 during mid-day trading on Wednesday, hitting $11.69. The company’s stock had a trading volume of 52,461 shares, compared to its average volume of 567,255. P3 Health Partners Inc. has a fifty-two week low of $1.52 and a fifty-two week high of $16.89. The company has a market capitalization of $84.64 million, a price-to-earnings ratio of -0.35 and a beta of 1.63. The stock has a fifty day moving average of $10.97 and a 200-day moving average of $6.47.

P3 Health Partners (NASDAQ:PIII) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.26. The company had revenue of $386.38 million for the quarter, compared to analyst estimates of $377.80 million.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Lake Street Capital reaffirmed a “buy” rating and issued a $23.00 price target on shares of P3 Health Partners in a research note on Tuesday. UBS Group set a $14.00 price target on P3 Health Partners in a research report on Friday, May 15th. Weiss Ratings upgraded P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 28th. Wall Street Zen raised P3 Health Partners to a “hold” rating in a report on Saturday, July 4th. Finally, TD Cowen restated a “hold” rating and issued a $14.00 target price (up from $3.00) on shares of P3 Health Partners in a research note on Friday, May 22nd. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $17.00.

Institutional Trading of P3 Health Partners

An institutional investor recently bought a new stake in P3 Health Partners stock. Diversified Trust Co purchased a new position in shares of P3 Health Partners Inc. (NASDAQ:PIII) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 20,316 shares of the company’s stock, valued at approximately $63,000. Diversified Trust Co owned approximately 0.28% of P3 Health Partners as of its most recent SEC filing. 7.75% of the stock is currently owned by institutional investors.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.